BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors

Neoplasms Clinical Trial

Official title:

An Open Label Phase I Dose Finding Study of BI 860585 Administered Orally in a Continuous Dosing Schedule as Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumours

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01938846
• Other study ID #: 1325.1
• Secondary ID: 2013-000765-36
• Status: Completed
• Phase: Phase 1
• Start date: September 5, 2013
• Est. completion date: June 22, 2017

Study information

• Verified date: June 2018
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of the trial is to determine the maximum tolerated doses (MTD) of BI 860585 alone and in combination with exemestane or paclitaxel. To determine the MTDs, patients are entered sequentially into escalating dose cohorts. Secondary objectives are objective response and disease control according to RECIST criteria version 1.1

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: June 22, 2017
• Est. primary completion date: July 30, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion criteria:

• Patients with histologically or cytologically confirmed diagnosis of advanced, measurable or evaluable, non-resectable and/or metastatic solid tumours, which has shown to be progressive;

• Patients who have received previous standard of care therapy for their disease and have progressed;

• 18 years or older;

• Life expectancy >= 3 months;

• Written informed consent in accordance with International Conference on Harmonisation/Good Clinical Practice (ICH/GCP) and local legislation;

• Eastern Cooperative Oncology Group (ECOG), performance score 0-2.

Additional inclusion criteria for the combination arms:

• Patients must have confirmed progressive disease within the last 6 months, (in case of measurable disease, progression should be confirmed according to Response Evaluation Criteria in Solid Tumours (RECIST) criteria version 1.1;

• Patients carrying a tumour for whom treatment with either exemestane or paclitaxel would be considered appropriate by the investigator;

Additional inclusion criteria for expansion part:

• Patients must have measurable progressive disease within the last 6 months documented/proven according to RECIST criteria version 1.1.

• Patients entering the expansion cohorts must also have:

• Arm A: any advanced/metastatic solid tumour suitable for biopsy and must have provided informed consent for biopsy and biomarker analysis.

• Arm B: any cytologically or histologically confirmed ER+ (estrogen receptor positive) advanced/metastatic solid tumours for which treatment with exemestane would be considered appropriate by the investigator.

• Arm C: any advanced/metastatic solid tumour for which treatment with paclitaxel would be considered appropriate by the investigator.

Exclusion criteria:

• Serious concomitant non-oncological disease/illness considered by the investigator to be incompatible with the protocol;

• Patients with untreated or symptomatic brain metastases;

• Second malignancies requiring active therapy;

• Clinical Congestive Heart Failure (CHF) Grade III-IV;

• Myocardial infarction within the last 6 months prior to inclusion, or symptomatic coronary artery disease;

• Adequate bone marrow, liver and renal function;

• Patients with known HIV/hepatitis/active infectious disease considered by the investigator to be incompatible with the protocol;

• Patients unable to take oral medication;

• Chronic diarrhoea or other gastrointestinal disorders;

• Treatment with anti-cancer-therapies: cytotoxic or standard chemotherapy, immunotherapy, radiotherapy, biological therapies, molecular targeted or other investigational drugs, within four weeks of the first treatment with the study medication (or within one week for non-cytotoxic drugs);

• Recovery from previous surgery and anticancer medical treatments;

• Hypersensitivity to combination drugs or excipients;

• Patients with a history of uncontrolled diabetes mellitus.

Related Conditions & MeSH terms

• Neoplasms

Intervention

Drug:
• BI 860585
BI 860585 multiple dose escalation, once daily
• exemestane
exemestane once daily
• BI 860585
BI 860585 multiple dose escalation, once daily
• BI 860585
BI 860585 multiple dose escalation, once daily
• paclitaxel
paclitaxel once weekly

Locations

Country	Name	City	State
Belgium	Brussels - UNIV Saint-Luc	Bruxelles
Belgium	UNIV UZ Gent	Gent
Italy	Fondazione IRCCS Istituto Nazionale dei Tumori	Milano
Italy	Azienda Ospedaliera di Parma	Parma

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Countries where clinical trial is conducted

Belgium,  Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Number of Patients With Dose-Limiting Toxicities (DLTs) in the First Course of Each Treatment Arm	The number of patients with Dose-Limiting Toxicities (DLTs) in the first course of each treatment arm to identify the Maximum Tolerated Dose (MTD) for BI 860585 monotherapy and BI 860585 in combination with exemestane of paclitaxel.	28 days (Maximum tolerated dose (MTD) evaluation period (First Treatment Cycle))
Primary	The Maximum Tolerated Dose (MTD) for Each Treatment Arm	The Maximum Tolerated Dose (MTD) for each treatment arm was the dose that was 1 dose cohort below that at which =2 of 6 patients had experienced DLT. i.e., the MTD was the highest dose studied for which the DLT incidence was no more than 17% (i.e. 1 of 6 patients) during the first treatment course.	28 days (Maximum tolerated dose (MTD) evaluation period (First Treatment Cycle))
Secondary	Objective Response Rate (Complete Response or Partial Response as Per the Response Evaluation Criteria In Solid Tumors Criteria [RECIST], Version 1.1)	As Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for objective response rate (Complete Response (CR), disappearance of all target lesions; Partial Response (PR), =30% decrease in the sum of the longest diameter of target lesions) for target lesions assessed by Magnetic resonance imaging (MRI) and Computed tomography (CT)	From the date of first treatment administration until the earliest of disease progression, death, or last adequate tumour assessment before new anti-cancer therapy; data collected up to cut-off date 30 Jun 2017, Up to 1389 days
Secondary	Disease Control Rate/Clinical Benefit Rate (Complete Response, Partial Response or Stable Disease as Per Response Evaluation Criteria In Solid Tumors Criteria [RECIST], Version 1.1)	As Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for disease control rate/clinical benefit rate (Complete Response (CR), disappearance of all target lesions; Partial Response (PR), =30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression) for target lesions assessed by Magnetic resonance imaging (MRI) and Computed tomography (CT)	From the date of first treatment administration until the earliest of disease progression, death, or last adequate tumour assessment before new anti-cancer therapy.
Secondary	Duration of Clinical Benefit	Duration of clinical benefit (Disease control) was defined as the time between first treatment administration until the earliest of disease progression or death, for patients with disease control.	From the date of first treatment administration until the earliest of disease progression, death, or last adequate tumour assessment before new anti-cancer therapy; data collected up to cut-off date 30 Jun 2017, Up to 1389 days
Secondary	Duration of Objective Response	Duration of objective response was defined as the time from first objective response until the earliest of progression or death, for patients with objective response.	From the date of first treatment administration until the earliest of disease progression, death, or last adequate tumour assessment before new anti-cancer therapy; data collected up to cut-off date 30 Jun 2017, Up to 1389 days
Secondary	Area Under the Concentration-time Curve in Plasma of BI 860585 Over the Time Interval From 0 to Infinity (AUC0-8)	AUC0-8, area under the concentration-time curve in plasma of BI 860585 over the time interval from 0 to infinity after single administration of BI 860585	Pharmacokinetic samples were collected at pre-dose and 0.5, 1, 2, 3, 4, 6, 8 and 23.917 hours after administration of BI 860585.
Secondary	Area Under the Concentration-time Curve in Plasma of BI 860585 Over the Time Interval From 0 to 24 Hours (AUC0-24)	AUC0-24, area under the concentration-time curve in plasma of BI 860585 over the time interval from 0 to 24 hours after single administration of BI 860585	Pharmacokinetic samples were collected at pre-dose and 0.5, 1, 2, 3, 4, 6, 8 and 23.917 hours after administration of BI 860585.
Secondary	Half Life of BI 860585 (t1/2)	t ½, half-life of BI 860585 in plasma over a dosing interval after single administration of BI 860585	Pharmacokinetic samples were collected at pre-dose and 0.5, 1, 2, 3, 4, 6, 8 and 23.917 hours after administration of BI 860585.
Secondary	Maximum Measured Concentration of BI 860585 (Cmax)	Cmax, maximum measured concentration of BI 860585 in plasma over a dosing interval after single administration of BI 860585	Pharmacokinetic samples were collected at pre-dose and 0.5, 1, 2, 3, 4, 6, 8 and 23.917 hours after administration of BI 860585.
Secondary	Time to Maximum Concentration of BI 860585 (Tmax)	Tmax, Time to maximum concentration of BI 860585 in plasma over a dosing interval after single administration of BI 860585	Pharmacokinetic samples were collected at pre-dose and 0.5, 1, 2, 3, 4, 6, 8 and 23.917 hours after administration of BI 860585.
Secondary	Area Under the Concentration-time Curve of BI 860585 in Plasma Over a Dosing Interval at Steady State (AUCt,ss)	AUCt,ss, area under the concentration-time curve of BI 860585 in plasma over the dosing interval at steady state after multiple administration of BI 860585 (Day 22) in BI 860585 monotherapy and in combination with exemestane and paclitaxel.	Pharmacokinetic samples were collected at pre-dose and at 504.5, 505, 506, 507, 508, 510, 512, 527.917 hours after drug administration.
Secondary	Half Life of BI 860585 at Steady State (t1/2,ss)	t1/2,ss, half-life of BI 860585 in plasma at steady state after multiple administration of BI 860585 (Day 22) in BI 860585 monotherapy and in combination with exemestane and paclitaxel.	Pharmacokinetic samples were collected at pre-dose and at 504.5, 505, 506, 507, 508, 510, 512, 527.917 hours after drug administration.
Secondary	Time to Maximum Concentration of BI 860585 at Steady State (Tmax,ss)	tmax,ss, Time to maximum concentration of BI 860585 at steady state after multiple administration of BI 860585 (Day 22) in BI 860585 monotherapy and in combination with exemestane and paclitaxel.	Pharmacokinetic samples were collected at pre-dose and at 504.5, 505, 506, 507, 508, 510, 512, 527.917 hours after drug administration.
Secondary	Maximum Measured Concentration of BI 860585 in Plasma at Steady State (Cmax,ss)	Cmax,ss, maximum measured concentration at steady state after multiple administration of BI 860585 (Day 22) in BI 860585 monotherapy and in combination with exemestane and paclitaxel.	Pharmacokinetic samples were collected at pre-dose and at 504.5, 505, 506, 507, 508, 510, 512, 527.917 hours after drug administration.

External Links

•   Link